Entrada Therapeutics (TRDA) Current Assets (2020 - 2026)

Entrada Therapeutics' Current Assets history runs 7 years deep, the most recent figure standing at $266.9 million for Q1 2026.

• On a quarterly basis, Current Assets fell 33.81% year-over-year to $266.9 million in Q1 2026; TTM through Mar 2026 was $266.9 million, a 33.81% decrease from a year earlier, with the FY2025 full-year figure at $306.3 million, down 30.4% from the prior year.
• Current Assets slipped to $266.9 million in Q1 2026 per TRDA's latest filing, from $306.3 million in the prior quarter.
• Across five years, Current Assets topped out at $489.5 million in Q2 2024 and bottomed at $209.9 million in Q4 2022.
• The 5-year median for Current Assets is $369.8 million (2023), against an average of $355.4 million.
• Across the five-year window, Current Assets soared 90.03% in 2022 and plunged 33.81% in 2026, its largest moves.
• Year by year, Current Assets stood at $209.9 million in 2022, then soared by 76.19% to $369.8 million in 2023, then rose by 19.0% to $440.0 million in 2024, then tumbled by 30.4% to $306.3 million in 2025, then slipped by 12.86% to $266.9 million in 2026.
• Per Business Quant, the three latest TRDA Current Assets figures stand at $266.9 million (Q1 2026), $306.3 million (Q4 2025), and $338.3 million (Q3 2025).